CEOs of both domestic and multinational pharmaceutical companies alike identified 'drug prices and reimbursement as in need of most regulatory improvement. CEOs of multinational pharmaceutical companies only gave a 2-point range satisfaction score in terms of satisfaction with Korea’s drug pricing and reimbursement regulations. This indicates how CEOs are even more dissatisfied with regulations that affect the management of pharmaceutical companies, such as new drug registration, generic reevaluation, and reimbursement reevaluations.

According to Dailypharm's survey of 53 CEOs of pharmaceutical companies, CEOs of both domestic and multinational pharmaceutical companies had a negative perception